Skip to content

Clinical Study of Oxycodone Combined with Dexmedetomidine in Drug-Induced Sleep Endoscopy

Clinical Study of Oxycodone Combined with Dexmedetomidine in Drug-Induced Sleep Endoscopy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600121480
Enrollment
Unknown
Registered
2026-03-31
Start date
2026-04-28
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The specific disease focused on in this study is Obstructive Sleep Apnea-Hypopnea Syndrome (OSA). Its core feature is the repeated occurrence of hypopnea and/or respiratory arrest during sleep due to upper airway collapse, often accompanied by symptoms such as snoring, sleep fragmentation, daytime somnolence, and inattention. Long-term episodes can also lead to chronic intermittent hypoxemia, hype

Interventions

Oxycodone Group (O Group):Oxycodone 0.04 mg/kg IV bolus + Dexmedetomidine loading dose 1 µg/kg infusion over 10 minutes, followed by infusion at 2-3 µg/(kg·h)
Dexmedetomidine Group (Y Group):Dexmedetomidine loading dose 1 µg/kg infusion over 10 minutes, followed by infusion at 2-3 µg/(kg·h)

Sponsors

Affiliated Hospital of Jiangnan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1.Preoperatively diagnosed with Obstructive Sleep Apnea-Hypopnea Syndrome (OSA) and scheduled to undergo Drug-Induced Sleep Endoscopy (DISE); 2.Classified as American Society of Anesthesiologists (ASA) Physical Status ?-?; 3.No history of chronic pain before surgery; 4.Aged 18-60 years; 5.Fully informed of the details of the anesthetic protocol in this study, voluntarily participate in the study, and sign a written informed consent form.

Exclusion criteria

Exclusion criteria: 1. Those with severe diabetes, heart disease or hypertension; 2. Those with severe abnormalities in liver and kidney functions; 3. Those with concurrent brain diseases, mental system diseases, immune system diseases, coagulation disorders, and chronic pain diseases; 4. Those with a long-term history of using analgesic and sedative drugs, a history of drug abuse, and a history of allergies

Design outcomes

Primary

MeasureTime frame
Success rate of sedation;

Secondary

MeasureTime frame
Total number of additional drug administrations after the first dose and number of jaw-thrust maneuvers;Incidence of adverse events;Incidence of severe hypoxemia;

Countries

China

Contacts

Public ContactHu Na

Affiliated Hospital of Jiangnan University

631943560@qq.com+86 510 68089100

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026